Nautilus Biotechnology (NAUT) Insider Posard Buys 45,000 Shares
Matthew Posard increased his holdings in Nautilus Biotechnology with a 45,000-share purchase.
Reviewed by automated data checks against the source filing. How we make and check alerts
Matthew Posard bought 45,000 shares of Nautilus Biotechnology, Inc. ($NAUT) on June 18, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $NAUT is down 0.4% after 1 week, down 25.9% after 1 month and down 9.7% to date (from the $2.28 close on Jun 18, 2026).
NAUT
Nautilus Biotechnology, Inc.
Key Points
- Matthew Posard increased his holdings in Nautilus Biotechnology by purchasing 45,000 shares on June 18, 2026.
- Shares of Nautilus Biotechnology traded near $2.31 on Tuesday, with recent insider buying activity boosting interest.
- A16Z Capital Management holds 17.65 million shares, while Vanguard Capital Management opened a new position with 2.55 million shares.
Get $NAUT trade alerts by text
We text you when insiders, Congress or big funds trade $NAUT. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Nautilus Biotechnology, Inc. alert may contain errors. Disclosures
Matthew Posard has increased his holdings in Nautilus Biotechnology by purchasing 45,000 shares on June 18, 2026. This insider transaction reflects ongoing interest in the company among its leadership.
Insider Buying and Selling at Nautilus Biotechnology, Inc.
On June 18, 2026, several insiders, including Matthew Posard, purchased shares in Nautilus Biotechnology. Posard acquired 45,000 shares, as did other insiders such as Matthew McIlwain, Karen Akinsanya, Melissa Epperly, and Farzad Nazem. Sujal Patel, the CEO, President, and Secretary, bought 25,000 shares at an average price of $2.61 on March 4, 2026. These transactions were not conducted under Rule 10b5-1 plans.
Other Institutional Activity in Nautilus Biotechnology
Several institutional investors have made moves regarding their positions in Nautilus Biotechnology. A16Z Capital Management holds approximately 17.65 million shares valued at $68.5 million, while Perceptive Advisors LLC maintains 12.59 million shares worth about $48.9 million. Vanguard Capital Management and Clearstead Advisors, LLC recently opened new positions, acquiring 2.55 million and 2.33 million shares, respectively, with values of $9.88 million and $9.04 million. Comprehensive Financial Management LLC holds 2.21 million shares valued at $8.57 million.
Analysts Set New Price Targets
Analysts have recently weighed in on Nautilus Biotechnology. On February 27, 2026, Guggenheim maintained its "buy" rating with a price target of $4. Goldman Sachs previously downgraded the stock to "sell" with a target of $1.75 on December 8, 2024. Morgan Stanley maintained a "hold" rating with a $5 target on July 31, 2024.
Bottom Line
Insider buying activity at Nautilus Biotechnology, including significant purchases by Matthew Posard and others, highlights ongoing interest in the company. Institutional investors are also adjusting their positions, with some opening new stakes. Analysts' mixed ratings suggest varying expectations for the company's future performance. As always, 13F filings and insider transactions offer a retrospective look at holdings and may not reflect current positions.
Related Filing Alerts
Source: Matthew Posard's Form 4 filing on $NAUT (Jun 18, 2026). Find the original filing: NAUT Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts